A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs AZD-1775 (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 07 Feb 2017 Planned number of patients changed from 65 to 77.
- 07 Feb 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2021.